Stockscreener 앱 받기
10.11
0.69%
-0.07
시장 영업 전:
10.52
0.41
+4.06%
Forte Biosciences Inc 주식(FBRX)의 최신 뉴스
How the (FBRX) price action is used to our Advantage - news.stocktradersdaily.com
What analysts say about Forte Biosciences Inc. stockConsistently high returns - Autocar Professional
Is Forte Biosciences Inc. a good long term investmentSuperior return velocity - Autocar Professional
What drives Forte Biosciences Inc. stock priceStrongest growth potential - PrintWeekIndia
Forte Biosciences Inc. Stock Analysis and ForecastGame-changing capital returns - jammulinksnews.com
WVVI Stock Analysis and ForecastFree Bull & Bear Market Updates - Jammu Links News
Why Forte Biosciences Inc. stock attracts strong analyst attentionHigh Potential Stock Ideas - Newser
What makes Forte Biosciences Inc. stock price move sharplySafe Entry High Exit Alerts - Newser
How Forte Biosciences Inc. stock performs during market volatilityTop Momentum Stock Pick - Newser
Forte Biosciences Sees Unusually Large Options Volume (NASDAQ:FBRX) - Defense World
Finance Watch: A Mini-Surge In Follow-On Offerings Follows Positive Updates - insights.citeline.com
Forte Biosciences (FBRX): A Strategic Buy in Biotech's High-Reward Arena - AInvest
individual investors who own 54% along with institutions invested in Forte Biosciences, Inc. (NASDAQ:FBRX) saw increase in their holdings value last week - Yahoo Finance
(FBRX) Investment Analysis and Advice - news.stocktradersdaily.com
Forte Biosciences, Inc.(NasdaqCM: FBRX) added to Russell 3000E Index - MarketScreener
FBRX SEC FilingsForte Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Forte Biosciences Sees Unusually High Options Volume (NASDAQ:FBRX) - Defense World
Stock Sell-Offs Trigger Market Turmoil For Firms - Finimize
Firm Advises Forte Biosciences on $75 Million Public Offering - Wilson Sonsini
Forte Biosciences (FBRX) Plans $75 Million Public Offering - GuruFocus
Forte Biosciences Announces Public Offering of Shares - TipRanks
Forte Biosciences announces data from trial in celiac disease for FB102 - Yahoo Finance
Forte’s celiac disease drug shows positive results in Phase 1b trial - Investing.com Nigeria
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study - New Castle News
Forte Biosciences (FBRX) Soars 16.75% on Positive Clinical Trial Results - AInvest
Valkyrie Balance Sheet Opportunities ETF (NYSEARCA:VBB) Trading 0.4% Higher – Here’s Why - Defense World
Traders Buy Large Volume of Call Options on Forte Biosciences (NASDAQ:FBRX) - Defense World
With Forte Biosciences Up 28%, Insider Buyers Count Their Returns - simplywall.st
(FBRX) Long Term Investment Analysis - news.stocktradersdaily.com
Forte Biosciences (FBRX) Receives Buy Rating as FB-102 Shows Blockbuster Potential | FBRX Stock News - GuruFocus
Forte Biosciences reports annual meeting results By Investing.com - Investing.com Nigeria
Forte Biosciences reports annual meeting results - Investing.com
Forte Biosciences Elects New Directors at Annual Meeting - TipRanks
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
Pre-market Movers: VIGL, CVM, KDLY, VTAK... - RTTNews
0.87%
0.17%
자본화:
|
볼륨(24시간):